Implementing a new HCV model of care for people who use drugs

Andrea Herranz Mochales, Camila A. Picchio, Aina Nicolàs, María Dolores Macià, María Victoria Fernández-Baca, Joaquín Serrano, Lucía Bonet, Marita Trelles, Andreu Sansó, Alicia R. Rubí, Antonio Zamora, Mercedes García-Gasalla, Maria Buti, Àngels Vilella, Jeffrey V. Lazarus

Table of contents

Table S1. Participants lost to follow-up at every study phase with reasons.

	Participants lost to follow-up n (%)
Phase 1 (no anti-HCV screening) [a]	**1 (0.1)**
Not showing up for the appointment	1 (100)
Not wanting to continue in the study	2 (13)
Outside the Balearic Islands	0 (0)
No longer at the study centre	2 (13)
Exitus	0 (0)
Unknown	1 (7)
Phase 2 (no HCV RNA screening) [b]	**14 (3)**
Not showing up for the appointment	9 (64)
Not wanting to continue in the study	2 (14)
Outside the Balearic Islands	0 (0)
No longer at the study centre	2 (14)
Exitus	0 (0)
Unknown	1 (7)
Phase 3 (no treatment initiation) [c]	**23 (14)**
Pending treatment prescription	9 (39)
Unstable patient situation	10 (43)
Medical contraindications	2 (9)
Not wanting to continue in the study	2 (9)
Phase 3 (no treatment completion) [d]	**10 (7)**
No longer at the study centre	7 (70)
Unstable patient situation	2 (20)
Unknown	1 (10)
Phase 4 (no SVR≥12 monitoring) [e]	**17 (14)**
Not showing up for the appointment	8 (47)
Not wanting to continue in the study	1 (6)
Outside the Balearic Islands	3 (18)
No longer at the study centre	1 (6)
Exitus	2 (12)
Unknown	2 (12)
Phase 4 (no re-screening) [f]	**734 (89)**
Not showing up for the appointment	0 (0)
Not wanting to continue in the study	1 (0.1)
Outside the Balearic Islands	1 (0.1)
No longer at the study centre	4 (0.5)
Exitus	2 (0.3)
Unknown	726 (99)

Notes: [a] Out of the overall participants (n=1,423). [b] Out of those anti-HCV+ (n=464). [c] Out of those with an active HCV infection (n=170). [d] Out of those who initiated HCV treatment (n=147). [e] Out of those who completed HCV treatment (n=124). [f] Out of those screened up until April 2022 (n=821).

Abbreviations: SVR≥12, sustained virologic response at ≥12 weeks after treatment completion.

Supplementary references

1. World Health Organization. Hepatitis C: key facts, 2024. Available: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c [Accessed 15 April 2024].
2. World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. https://www.who.int/publications/i/item/9789240053779 (2022).
3. Picchio CA, Lens S, Hernández-Guerra M, *et al.* Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. *Scientific Reports* **11**, 1–12 (2021).
4. Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. *Int J Cancer* **142**, 2471–2477 (2018).
5. Rumgay H, Arnold M, Ferlay J, *et al.* Global burden of primary liver cancer in 2020 and predictions to 2040. *Journal of Hepatology* **77**, 1598–1606 (2022).
6. Pawlotsky JM, Negro F, Aghemo A, *et al.* EASL recommendations on treatment of hepatitis C: Final update of the series☆. *Journal of Hepatology* **73**, 1170–1218 (2020).
7. Gamkrelidze I, Pawlotsky JM, Lazarus JV, *et al.* Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. *Liver Int* **41**, 456–463 (2021).
8. Kondili LA, Craxì A, Aghemo A. Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements. *Liver Int* **41**, 649–655 (2021).
9. Lazarus JV, Pericàs JM, Picchio CA, *et al.* We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. *J Intern Med* **286**, 503–525 (2019).
10. Lazarus JV, Picchio CA, Byrne CJ, *et al.* A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination. *Seminars in Liver Disease* **42**, 159–172 (2022).
11. Lazarus JV, Safreed-Harmon K, Thursz MR, *et al.* The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. *Seminars in Liver Disease* **38** 181–192 (2018).
12. Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination - A path to global elimination of hepatitis C. *Journal of Hepatology* **67**, 665–666 (2017).
13. Harris M, Guy D, Picchio CA, *et al.* Conceptualising hepatitis C stigma: A thematic synthesis of qualitative research. *International Journal of Drug Policy* **96**, 103320 (2021).
14. Lazarus JV, Baker L, Cascio M, *et al.* Novel health systems service design checklist to improve healthcare access for marginalised, underserved communities in Europe. *BMJ Open* **10**, (2020).
15. Balsom CR, Farrell A, Kelly DV. Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs - a scoping review of the qualitative evidence. *BMC Public Health* **23**, 1038 (2023).

16. Joint United Nations statement on ending discrimination in health care settings. https://apps.who.int/iris/handle/10665/259622 [Accessed 07 June 2023].
17. Crespo J, Lázaro P, Blasco AJ, *et al.* Hepatitis C reflex testing in Spain in 2019: A story of success. *Enferm Infecc Microbiol Clin (English ed.)* **39**, 119–126 (2021).
18. Saludes V, Antuori A, Lazarus JV, *et al.* Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain. *International Journal of Drug Policy* **80**, (2020).
19. Martínez-Campreciós J, Rando-Segura A, Buti M, *et al.* Reflex viral load testing in dried blood spots generated by plasma separation card allows the screening and diagnosis of chronic viral hepatitis. *J Virol Methods* **289**, (2021).
20. Oru E, Trickey A, Shirali R, *et al*. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. *Lancet Glob Health* **9**, e431–e445 (2021).
21. Day E, Broder T, Bruneau J, *et al.* Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. *International Journal of Drug Policy* **66**, 87–93 (2019).
22. Day E, Hellard M, Treloar C, *et al.* Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. *Liver Int* **39**, 20 (2019).
23. Ministry of Health Social Services and Equality (Spain). *Guía de cribado de la infección por el VHC* (2020).https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/GUIA_DE_CRIBADO_DE_LA_INFECCION_POR_EL_VHC_2020.pdf [Accessed 05 May 2023].
24. Alianza para la Eliminación de las Hepatitis Víricas en España. Objetivo 2021 | AEHVE - Alianza para la Eliminación de las Hepatitis Víricas en España. http://aehve.org/objetivo-2021/ (2019) [Accessed 18 May 2023].
25. Crespo J, Albillos A, Buti M, *et al.* Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). *Rev Esp Enferm Dig* **42**, 579–592 (2019).
26. Lazarus, J. V. *et al.* Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care. *BMJ Open* **11**, e053394 (2021).
27. Lens S, Miralpeix A, Gálvez M, *et al.* HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates. *Journal of Hepatology* **4**, 100580 (2022).
28. Ryan P, Valencia J, Cuevas G, *et al.* HCV screening based on dried blood samples and linkage to care in people who use drugs: A prospective study. *International Journal of Drug Policy* **92**, (2021).

29. Forns X, Colom J, García-Retortillo M, *et al.* Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination. *Journal of Viral Hepatitis* **29**, 227–230 (2022).
30. Jiménez Galán G, Alia Alia C, Vegue González M, *et al.* The contribution of telemedicine to hepatitis C elimination in a correctional facility. *Rev Esp Enferm Dig* **111**, 550–555 (2019).
31. Cunningham EB, Wheeler A, Hajarizadeh B, *et al.* Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* **7**, 426-445 (2022).
32. Litwin AH, Lum PJ, Taylor LE, *et al.* Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. *Lancet Gastroenterol Hepatol* **7**, 1112–1127 (2022).
33. Demant J, Krohn-Dehli L, Van der Veen J, *et al.* Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark. *International Journal of Drug Policy* **121**, 104185 (2023).
34. Lazarus JV, Øvrehus A, Demant J, *et al*. The Copenhagen test and treat hepatitis C in a mobile clinic study: A protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T'N'T HepC). *BMJ Open* **10**, (2020).
35. Hutton J, Doyle J, Zordan R, *et al.* Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department. *International Journal of Drug Policy* **72**, 84–90 (2019).
36. Oru E, Verster A. Access to hepatitis C care for people who inject drugs and people in prisons. *Lancet Gastroenterol Hepatol* **4**, 662–663 (2019).
37. Grebely J, Hajarizadeh B, Lazarus JV, et al. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. *International Journal of Drug Policy* **72**, 1–10 (2019).
38. Hajarizadeh B, Cunningham EB, Reid H, *et al.* Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* **3**, 754–767 (2018).
39. Macías J, Morano LE, Téllez F, *et al.* Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. *Journal of Hepatology* **71**, 45–51 (2019).
40. Messina V, Onorato L, Di Caprio G, *et al.* Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. *Life (Basel)* **11**, 1–9 (2021).
41. Not A, Saludes V, Gálvez M, *et al.* Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program. *J Med Virol* **95**, (2023).

42. Rosato V, Nevola R, Conturso V, *et al.* Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic. *Biology (Basel)* **11**, 800 (2022).
43. Delegación del Gobierno para el Plan Nacional sobre Drogas. *National Strategy on Addictions, 2017.* https://pnsd.sanidad.gob.es/pnsd/Introduccion/home.htm [Accessed 05 May 2023].
44. Ministry of Health, Social Services and Equality. Strategic Plan for Tackling Hepatitis C in the Spanish National Health System (2015). https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/PEAHC_eng.pdf [Accessed 18 May 2023].
45. Marshall AD, Pawlotsky JM, Lazarus JV, *et al.* The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. *Journal of Hepatology* **69**, 1188–1196 (2018).
46. Barocas JA. 100–100–100: a new, ambitious treatment target to end the HIV and hepatitis C epidemics. *Lancet Public Health* **7**, e98–e99 (2022).
47. Rivero-Juarez A, Téllez F, Mayorga MI, *et al.* Progression to hepatitis C virus micro-elimination in people living with HIV in Spain. *Clin Microbiol Infect* **27**, 800–801 (2020).
48. Byrne C, Robinson E, Rae N, Dillon JF. Toward microelimination of hepatitis C and HIV coinfection in NHS Tayside, Scotland: Real-world outcomes. *Health Sci Rep* **3**, (2020).